-
The Ministry of Finance has invested more than 26.5 billion yuan in medical infrastructure! A new round of pharmaceutical procurement is rising!
Time of Update: 2022-11-26
On November 17, the medical device sector was still relatively active, and Huangshan capsules were up and down intraday, and they had closed 3 consecutive limit plates; Aipeng Medical closed up 14. 2
-
BeiGene starts overtaking in a corner? National talks are coming, domestic PD-1 commercialization competition!
Time of Update: 2022-11-26
For the PD-1 monoclonal antibody "domestic tigers" of Innovent Biologics, Hengrui Pharmaceutical, BeiGene, and Junshi Biologics, which have long been included in medical insurance, the highlight of this year's medical insurance negotiations is to see the competition for new indications into medical insurance.
-
Under the favorable policy, domestic pharmaceutical companies began to focus on the research and development of children's anti-tumor drugs
Time of Update: 2022-11-26
js?cdnversion='+~(-new Date()/36e5)];Recently, CDE issued a notice to publicly solicit opinions on the "Technical Guidelines for Clinical R&D of Children's Antineoplastic Drugs", which covers four major chapters, including background, overall considerations for clinical R&D of pediatric antineoplastic drugs, clinical R&D paths for pediatric antineoplastic drugs, and issues requiring special attention, and the time limit for soliciting comments is 1 month from the date of issuance.
-
Under the accelerated internationalization of local pharmaceutical companies, another domestic PD-1 product applied for going overseas!
Time of Update: 2022-11-26
Teripulimab is an anti-PD-1 monoclonal antibody drug independently developed by Junshi Biologics, and the submission of the marketing authorization application (MAA) to EMA means that after China and the United States, the global commercialization of teripulimab has begun to expand to Europe.
-
$2.8 billion in large varieties to meet the fierce enemy, Huahai, Dongguang Medicine... 63 ANDAs were acquired
Time of Update: 2022-11-26
com From the perspective of the number of ANDA approvals in recent years, it reached the highest level in 2017, and the policy of "going overseas and reporting to China" has increased the speed of approval of relevant generic drugs in China, which will help domestic pharmaceutical companies quickly seize the market.
-
Do not "fill in the blanks" for the decline in the proportion of drugs, and change the price of medical services to the same frequency as residents' income
Time of Update: 2022-11-26
criteriaof drugs Compared with the two programs, the increase in income generated by social and economic development is undoubtedly the resource space for medical service price reform.
-
Under the high prosperity of China's API industry, there is good news recently
Time of Update: 2022-11-26
js?cdnversion='+~(-new Date()/36e5)];China is a major producer and exporter of APIs, with the continuous expansion of the pharmaceutical market, APIs as the basic raw materials for drug production, the market scale is increasing year by year, and the layout of related pharmaceutical companies in products is also accelerating.
-
Raw materials such as white peony rose, and the profit of TusPharmaceutical decreased
Time of Update: 2022-11-26
Fourth, the market analysis of the core raw materials of Guhan health essence Ginseng, the production area of the new end, affected by the epidemic, the origin transaction is not fast, new goods have arrived on the market, the market has recently moved in small batches better, the market has maintained a firm operation, the price of 45 live drying sticks is between 350-360 yuan (kilogram price, the same below).
-
New drugs for rare diseases! AstraZeneca C5 complement inhibitor Soliris (Suliri, ® eculizumab) is launched in China!
Time of Update: 2022-11-26
Nov. 12, 2022 /Biovalley BIOON/ -- AstraZeneca today announced that its rare disease group Alexion has launched its first rare disease therapy in China: Soliris (trade name: eculizumab, eculizumab) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in adults and children in China 。 This marks a significant expansion of AstraZeneca's global footprint in rare diseases following the acquisition of Alexion in 2021.
-
Announcement of the draft standard for gas impurity determination - gas detection tube method
Time of Update: 2022-11-26
cn Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahuanan Li, Dongcheng District, Beijing Zip code: 100061 Annex: Gas Impurity Determination - Draft Publicity of the Draft Standard for Gas Detection Tube Method National Pharmacopoeia Commission November 08, 2022 In order to ensure the scientificity, rationality and applicability of the standard, the proposed pharmaceutical excipient standard is now publicized to solicit opinions from all walks of life (see Annexes 1 and 2 for details).
-
Valsartan reduced to 0.1 yuan per tablet, how should pharmaceutical companies cope with the challenge of cost reduction and cost control?
Time of Update: 2022-11-26
However, from the perspective of industry analysis, the antihypertensive drug market will not be greatly affected, because on the one hand, the new 300 million hypertensive patients do not necessarily need to take medicine, and second, under the centralized procurement and price reduction, the opportunity for antihypertensive drugs to be administered to companies to make money is very small.
-
National Health Insurance Administration: The participation rate of basic medical insurance in the country from January to September was stable at 95%
Time of Update: 2022-11-26
149118 billion yuan, a year-on-year increase of 5.
149118 billion yuan, a year-on-year increase of 5.
149118 billion yuan, a year-on-year increase of 5.
149118 billion yuan, a year-on-year increase of 5.
149118 billion yuan, a year-on-year increase of 5.
-
At the end of the year, the pharmaceutical circle once again staged a "big drama", selling assets, stopping production at the base ...
Time of Update: 2022-11-26
From the public information, since October this year, Harbour Pharma has made frequent moves, not only selling factories, but also announcing the end of its phase III clinical trial of tenacept (HBM9036) in China because of insufficient efficacy.
-
Proprietary Chinese medicine is ushering in a period of opportunity and challenge to embrace chronic diseases!
Time of Update: 2022-11-26
(Image source: Pharma Network) Opportunities have emerged Chronic diseases refer to a group of clinical diseases with a long course of disease, complex etiology, health damage and social harm, common including hypertension, diabetes, cardiovascular and cerebrovascular diseases, malignant tumors, etc.
-
The State Food and Drug Administration announced the third batch of typical cases of special rectification of drug safety
Time of Update: 2022-11-26
Since the beginning of this year, in order to implement the decision-making and deployment of the Party Central Committee and the State Council on strengthening drug safety, the State Food and Drug A
-
The Ministry of Civil Affairs issued a document clarifying that administrative inspections of old-age care institutions must not affect their normal business activities
Time of Update: 2022-11-26
sportsof enterprises The Measures are divided into 5 chapters and 41 articles, focusing on the three key links of administrative inspection source, process and result, focusing on detailing the types of inspections, clarifying the requirements of each link of inspection, and strengthening the supervision and management of inspection behavior.
-
CDE issued a notice on the "Technical Guidelines for Pharmaceutical Research of Ethanol Dose Pouring Test for Oral Controlled Release Preparations of Chemical Generic Drugs"
Time of Update: 2022-11-26
. pdf In order to standardize and guide the pharmaceutical research and development of oral modulated release preparations of chemical generic drugs, under the deployment of the State Medical Products Administration, the Center for Drug Review organized and formulated the "Technical Guidelines for Pharmaceutical Research of Ethanol Dose Pouring Test of Oral Modulated Release Preparations of Chemical Generic Drugs" (see annex).
-
The CDE issued a notice on the "Changes in the Working Procedures during the Review of Drug Registration Applications (Trial)"
Time of Update: 2022-11-26
Annex: Changes to the Working Procedures During the Review of Drug Registration Applications (Trial) Drug Review Center, State Food and Drug Administration November 9, 2022 Related attachments serial number Attachment name 1 .
-
One year after the end of the pilot, the traditional Chinese medicine formula granule industry is moving towards high standards
Time of Update: 2022-11-26
Under the high threshold and high standard, in the past year, the market pattern of the traditional Chinese medicine formula granule industry has been adjusted steadily: those who have entered the game have made efforts to improve core competitiveness such as product quality, and those who intend to enter the game carefully observe and do what they can.
-
Since November, a number of Class 1 new drugs have been approved for marketing in China
Time of Update: 2022-11-26
Hengrui/Yingli Pharmaceutical's blockbuster Class 1 new drug was approved for marketing On November 9, the State Food and Drug Administration (NMPA) conditionally approved the marketing of Linperlisib, a Class 1 innovative drug (trade name: Intarui), of Shanghai Yingli Pharmaceutical, through the priority review and approval process, which is suitable for adult patients with relapsed or refractory follicular lymphoma who have received at least two previous systemic treatments.
